New Drug Doubles Brain Tumor Survival Time

Vorasidenib, or Voranigo, is a groundbreaking new drug for adult brain tumors, approved by the NHS after two decades. It targets specific genetic markers in astrocytoma and oligodendroglioma, showing promising results. Jodie Goulbourn, a patient who joined a clinical trial, experienced life-changing improvements, regaining confidence and starting a new job. The trial results, published in The Lancet Oncology, showed significant benefits, leading to its approval for routine use in England and Wales. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6c42366b907a3453